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During  the  2009  influenza  pandemic,  a  monovalent 
AS03-adjuvanted vaccine was almost exclusively used 
in  Germany  for  immunisation  against  the  2009  pan-
demic influenza A(H1N1) virus. One-dose vaccination 
was recommended for all age groups. We applied the 
screening method for the rapid assessment of vaccine 
effectiveness  (VE)  based  on  reported  data  of  vacci-
nated and unvaccinated pandemic influenza cases and 
vaccination  coverage  estimates.  Preliminary  results 
demonstrate excellent VE in persons aged 14-59 years 
(96.8%; 95% confidence interval (CI): 95.2-97.9) and 
moderately high VE in those 60 years or older (83.3%; 
95% CI: 71.0-90.5). 
Introduction
In  Germany,  vaccination  against  pandemic  influenza 
A(H1N1)  2009  was  initiated  on  26  October  (calendar 
week 44) with the monovalent AS03-adjuvanted H1N1-
vaccine  Pandemrix®  containing  3,25  µg  haemagglu-
tinin.  At  the  onset  of  the  vaccination  campaign,  the 
number of reported pandemic influenza cases had just 
begun to rise rapidly and eventually peaked in week 47 
(Figure 1). 
A  non-adjuvanted  vaccine  was  introduced  seven 
weeks later but was restricted to pregnant women. In 
a randomised clinical trial a higher dose of the AS03-
adjuvanted vaccine (5.25 µg haemagglutinin) showed 
seroconversion  and  seroprotection  rates  over  96% 
after one shot [1]. Based on these data, the German 
regulatory authority recommended that one dose was 
sufficient  for  immunisation  against  2009  pandemic 
influenza A(H1N1). While immunogenicity data remain 
the basis for licensure of these vaccines, it is unknown 
how well they correlate with protection [2]. Therefore, 
it  is  essential  to  estimate  vaccine  effectiveness  (VE) 
from post-marketing surveillance data to confirm that 
the  one-dose  vaccination  regimen  induces  sufficient 
protection  in  different  age  and  risk  groups  [3].  Here 
we present results from the analysis of breakthrough 
infections reported through the statutory disease noti-
fication  system  in  Germany  and  report  VE  estimated 
using the screening method [4,5]. 
Methods
With  onset  of  the  pandemic,  influenza  surveillance 
in  Germany  was  intensified.  Notified  2009  pandemic 
influenza  A(H1N1)  cases  were  interviewed  by  local 
public health officials for underlying chronic diseases, 
hospitalisation, and influenza vaccination status. Data 
from  studies  on  seasonal  influenza  vaccines  showed 
that protective antibodies are present in over 90% of 
persons  14  days  after  vaccination  [6].  Therefore  we 
defined  vaccine  failure  as  laboratory-confirmed  pan-
demic influenza in a person vaccinated more than 14 
days  prior  to  illness  onset.  Potential  risk  factors  for 
vaccine  failure  were  assessed  by  comparing  vaccine 
failure cases with persons vaccinated during the seven 
days prior to disease onset. The latter group was con-
sidered as representative of vaccinated persons in gen-
eral and, assuming reasonably high VE it should have 
included  only  a  small  proportion  of  individuals  who 
would have shown true vaccine failure had the infec-
tion occurred at a later point in time. For multivariate 
analysis, logistic regression models were applied using 
stepwise backward removal with inclusion of age, sex, 
and all variables with a p-value of ≤0.2 in univariate 
analysis in the first step. 
To  monitor  pandemic  influenza  vaccine  uptake  in 
Germany,  a  computer-assisted  telephone  survey  was 
carried  out  during  the  vaccination  campaign  starting 
in calendar week 47. A randomly selected representa-
tive sample of 1,000 individuals of 14 years or older 
was interviewed at two week intervals. Demographic 
information,  influenza  vaccination  status  (receipt  of 
2009-10 seasonal influenza vaccine or 2009 pandemic 
influenza vaccine, including month of vaccination), as 
well as knowledge of and attitude towards pandemic 
influenza  vaccination  were  elicited  using  a  standard-
ised questionnaire. Average vaccination coverage and 
95% confidence interval (CI) were weighted for repre-
sentativeness of the target population. We estimated 
VE by using the following formula: 
VE = (PPV-PCV) / PPV(1-PCV) x 100%3 www.eurosurveillance.org
where PPV is the proportion vaccinated in the popula-
tion and PCV the proportion of vaccinated cases [4]. 
Laboratory-confirmed pandemic influenza cases noti-
fied in all German federal states from week 47 in 2009 
(the week when first vaccination coverage data were 
available, i.e. three weeks after initiation of the vacci-
nation campaign) to week four in 2010 were included 
in the analysis. Since the exact date of vaccination and 
symptom  onset  were  not  available  for  all  vaccinated 
cases, an expansion factor was calculated by dividing 
the total number of cases vaccinated against pandemic 
influenza by the number of vaccinated cases with avail-
able information (Table). 
Results
From  week  47  in  2009  to  week  four  in  2010,  a  total 
of  71,315  laboratory-confirmed  pandemic  influenza 
cases were notified. Of 45,733 cases with information 
available, 425 (0.93%) were reported to be vaccinated 
against pandemic influenza. Figure 2 shows the distri-
bution of vaccinated cases by number of days between 
date of vaccination and disease onset: 180 were vac-
cinated seven days or less, 48 cases 8-14 days, and 
61 cases more than 14 days prior to disease onset (136 
cases with missing data on vaccination date or symp-
tom onset). 
In  univariate  analysis,  age  (proportion  of  cases  60 
years  or  older:  11.4%  among  vaccine  failures  versus 
3.6% among cases vaccinated seven days or less prior 
Figure 1
Number of reported pandemic influenza cases by calendar week, Germany, week 42, 2009 - week 4, 2010 
The vaccination campaign was initiated in week 44, 2009 (indicated by the black arrow).
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
50,000
42 43 44 45 46 47 48 49 50 51 52 53 1 2 3 4
Calendar week 2009-10
N
u
m
b
e
r
 
o
f
 
r
e
p
o
r
t
e
d
 
c
a
s
e
s
 
o
f
 
2
0
0
9
 
p
a
n
d
e
m
i
c
 
i
n
ﬂ
u
e
n
z
a
Table 
Pandemic influenza 2009 A(H1N1) vaccine effectiveness for individuals ≥14 years of age, estimated by the proportion of 
pandemic influenza cases with vaccine failure reported among all laboratory-confirmed cases in routine surveillance and 
the proportion vaccinated in the general population, Germany, week 47, 2009 – week 4, 2010
Age 
groups 
(years)
H1N1 
cases 
(total)
H1N1 cases with vacci-
nation status available
Vaccine 
failures 
(cases with 
disease >14 
days after 
vaccination)
Expansion factor  
(total vaccinated 
cases / vaccinated 
cases with informa-
tion on date of vacci-
nation and symptom 
onset) 
Vaccine 
failures  
(after apply-
ing expansion 
factors)
Proportion H1N1 
cases with vaccine 
failure among H1N1 
cases with avail-
able vaccination 
status
Proportion vac-
cinated in the 
general popu-
lation (95%CI)
Vaccine 
effective-
ness 
(95%CI)
Cases not 
vaccinated 
against 
H1N1
Cases 
vaccinat-
ed against 
H1N1
14-59 37,756 23,853 219 35 1.52 (219 / 144) 53.2 0.0022
0.064  
(0.044-0.093)
96.8% 
(95.2-97.9)
≥60 1430 923   25   7 1.92 (25 / 13) 13.4 0.0141
0.079  
(0.047-0.131)
83.3% 
(71.0-90.5)4 www.eurosurveillance.org
to  symptom  onset,  p=0.027)  and  previous  seasonal 
influenza vaccination (61.8% versus 41.0%, p=0.008) 
were  associated  with  2009  pandemic  influenza  vac-
cine  failure.  Underlying  chronic  disease  (40.0%  ver-
sus  28.1%,  p=0.093)  and  hospitalisation  (9.8%  vs. 
12.7%, p=0.53) were not significantly associated with 
vaccine failure. In multivariate logistic regression only 
age  remained  independently  associated  with  vac-
cine failure (odds ratio (OR)= 1.82; 95% CI 1.03-3.21). 
Immunosuppression was reported for two (3.3%) cases 
in  the  vaccine  failure  group  and  five  (3.0%)  in  the 
control group. None of the vaccine failure cases were 
pregnant. 
The vaccination coverage assessment included a total 
of 6,009 household interviews and revealed an aver-
age pandemic influenza vaccination coverage of 6.8% 
(95% CI 5.0-9.2) for Germany in persons 14 years and 
older. VE was estimated at 96.8% (95% CI 95.2-97.9) 
for all persons aged 14-59 years and at 83.3% (95% CI 
71.0-90.5) for persons 60 years or older (Table).
Conclusions 
A comparison of the prevalence of potential risk fac-
tors for vaccine failure in the group of cases vaccinated 
in the seven days before disease onset (proxy for suc-
cessfully  vaccinated  persons)  with  that  in  the  group 
of vaccine failure cases revealed only older age to be 
significantly associated with vaccine failure, in keep-
ing  with  the  findings  from  the  screening  analysis.  A 
Cochrane review has shown high VE of seasonal influ-
enza vaccines up to 80% against laboratory-confirmed 
seasonal  influenza  in  healthy  adults  aged  16  to  65 
years in seasons in which the vaccine matched circulat-
ing strains [7]. In contrast, reviews on the effectiveness 
of seasonal influenza vaccination in the elderly have 
shown  low  or  uncertain  effectiveness  [8,  9].  These 
reviews  identified  a  lack  of  high  quality,  unbiased 
studies using the specific end-point of laboratory-con-
firmed influenza. A few studies on the effectiveness of 
adjuvanted seasonal influenza vaccine were included 
in the Cochrane review on VE in the elderly [8] and all 
used non-specific end-points such as preventing influ-
enza-like  illness  (ILI),  hospitalisation,  or  emergency 
admissions for pneumonia. However, use of adjuvan-
ted vaccines seems to be a promising approach lead-
ing to improved immune responses compared with the 
conventional vaccines [10]. While lower than in younger 
adults, our results also suggest an acceptable effec-
tiveness  of  the  AS03-adjuvanted  pandemic  influenza 
vaccine in preventing laboratory-confirmed pandemic 
influenza in the elderly, which should be confirmed in 
further analytical studies.
A statistically significant association of vaccine failure 
with  underlying  chronic  disease  was  not  found,  sug-
gesting that on the whole, the vaccine is effective in 
chronically ill persons. However, as this group is rather 
inhomogeneous, an association of vaccine failure with 
Figure 2
Time from pandemic influenza vaccination to date of symptom onset in 298 reported  cases with laboratory-confirmed 
2009 pandemic influenza A(H1N1) and information on exact date of vaccination and symptom onset, Germany , calendar 
week 47, 2009 - 4, 2010
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certain diagnoses or therapies cannot entirely be ruled 
out. 
The  screening  method  is  a  quick  and  simple  tool  to 
assess  VE  in  a  population  with  known  vaccination 
coverage. With reasonably accurate estimates of vac-
cination coverage, this technique can provide a rough 
guide as to whether further evaluation is necessary [5]. 
Strengths of our study were the statutory notification 
of infections with the 2009 pandemic influenza A(H1N1) 
virus in Germany, the occurrence of more than 70,000 
laboratory-confirmed  pandemic  influenza  cases  after 
the implementation of the vaccination campaign, and 
the availability of only one vaccine type against pan-
demic  influenza.  However,  it  is  possible  that  vacci-
nated patients with ILI might have been less frequently 
tested for pandemic influenza compared with unvacci-
nated persons, thereby potentially leading to VE over-
estimation. Thus, our results must be regarded as an 
upper-limit estimate. They nevertheless suggest excel-
lent VE of the AS03-adjuvanted pandemic vaccine after 
one dose with lower but still acceptable VE in elderly 
persons.
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Mayaro  virus  (MAYV)  disease  is  a  mosquito-borne 
zoonosis endemic in humid forests of tropical South 
America.  MAYV  is  closely  related  to  other  alphavi-
ruses that produce a dengue-like illness accompanied 
by long-lasting arthralgia. A French tourist developed 
high-grade fever and severe joint manifestations fol-
lowing a 15-day trip in the Amazon basin, Brazil, and 
was diagnosed with MAYV infection in January 2010. 
This case is the first reported in a traveller returning 
from an endemic South American country to Europe.
Introduction
Mayaro  virus  (MAYV)  (family  Togaviridae,  genus 
Alphavirus)  is  an  arthropod-borne  zoonotic  patho-
gen circulating only in tropical South America [1]. The 
transmission cycle of MAYV in the wild is nearly simi-
lar to the continuous sylvatic cycle of yellow fever and 
is believed to involve wild primates (monkeys) as the 
reservoir  and  the  tree-canopy-dwelling  Haemagogus 
mosquito  as  the  vector.  Thus,  human  infections  are 
strongly  associated  with  recent  exposure  to  humid 
tropical forest environments [1,2]. MAYV disease is an 
acute, self-limited dengue-like illness of three to five 
days’  duration.  Moreover,  MAYV  is  closely  related  to 
chikungunya virus and produces a nearly indistinguish-
able, highly debilitating arthralgic disease [1-3]. 
Here we report the case of MAYV disease that recently 
occurred in a French citizen who presented with severe 
rheumatologic  disorders  after  visiting  the  Brazilian 
Amazon.  This  report  illustrates  that  with  increasing 
travel to remote areas, travellers are at risk of acquir-
ing  and  importing  rare  diseases  that  are  not  indige-
nous to Europe.
Case report
The patient, a man in his late 20s, came to the travel 
clinic  of  the  Department  of  Internal  Medicine  and 
Tropical  Diseases  of  the  University  Hospital  Centre, 
Bordeaux,  France  on  4  January  2010  with  persistent 
incapacitating arthralgia for a two-month period and 
predominating in his knees and joints of the hands.
Figure
Timeline for travel history and symptoms in a French traveller with Mayaro virus disease, October 2009 - January 2010
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The patient had travelled in the Amazon forest region 
for two weeks in October and November 2009 for the 
purpose of fishing and butterfly hunting. He stayed for 
two days in Manaus, Amazonas, Brazil, and for a fur-
ther  two  days  at  Barcelos,  Amazonas,  north-western 
Brazil, before travelling in a dugout canoe along the 
Rio Negro River for ten days to the confluence area of 
the Demini River with the Araca River, a forest place 
situated 70 miles north of Barcelos. After another two 
days in Barcelos, he returned to France via Manaus and 
Sao Paulo (Figure).
During his second stay in Barcelos, in early November, 
he developed symptoms assumed to be related to den-
gue virus infection, with high-grade fever, headache, 
generalised  myalgia  and  diffuse  arthralgia.  Macular 
and partially confluent transient exanthema mainly on 
his arms appeared around the fifth day of illness. After 
his return to France, the patient had increasingly diffi-
culty walking and was severely impaired in daily activi-
ties because of severe recurrent joint pains. 
The patient had received yellow fever vaccine 10 years 
before. During the trip to the Amazon, he had taken 
doxycyclin as prophylaxis for malaria. 
When  he  presented  to  our  centre  on  5  January  2010 
(two months after onset of symptoms), the patient com-
plained  of  persistent  headache,  myalgia  and  severe 
symmetrical joint pains (wrists and ankles). At the time 
of presentation, laboratory tests showed a leukocyte 
cell count of 6,600 cells/µL and a thrombocyte count of 
177,000 platelets/µL. No markers of autoimmunity were 
found, notably anti-citrullin peptide antibodies or anti-
nuclear antibodies. He was negative for the major his-
tocompatibility  complex  HLA  B27  gene.  Concurrently, 
serologic status for dengue, chikungunya and yellow 
fever  viruses  as  well  as  MAYV  was  evaluated  using 
IgM  capture  and  IgG  sandwich  ELISA  at  the  National 
Reference  Centre  for  Arboviruses,  Institut  Pasteur, 
Paris. Serology for MAYV revealed positive results for 
specific  IgM  (optical  density  [OD]=0.34;  serum  con-
trol OD=0.122). OD values for specific IgG were nega-
tive (OD=0.082; serum control OD=0.092). The other 
serological results were negative, as well as tests for 
leptospirosis,  rickettsiosis,  Q  fever,  cytomegalovirus 
and Plasmodium falciparum malaria. Five weeks later, 
on 8 February 2010, MAYV antibody serology showed 
persistence  of  specific  IgM  (OD=0.494;  serum  con-
trol OD=0.116) and a lack of immunoglobulin switch-
ing from IgM to IgG (OD for IgG=0.076; serum control 
OD=0.084).
The  patient  recovered  completely,  although  severe 
joint  pain  persisted  for  eight  further  weeks  until  10 
April  despite  symptomatic  treatment.  The  diagnosis 
of a presumptive case of MAYV infection diagnosed by 
serology was established.
Discussion
To the best of our knowledge, this case is the first pub-
lished report of MAYV disease in a traveller returning 
to Europe. The presenting symptoms and signs were 
almost identical to those reported in previous clinical 
descriptions  of  the  disease  [2,4,5].  In  this  case,  the 
decision to test for a rather exotic virus such as MAYV 
was  based  on  several  factors:  the  patient’s  detailed 
travel history in tropical South America, which allowed 
risk factors to be identified such as potential exposure 
to vectors carrying diseases endemic in that area; the 
clinical presentation with incapacitating arthralgia fol-
lowing acute febrile illness; and finally, the expertise 
and technical tools available in the specialist clinic for 
tropical medicine where the patient was treated. Other 
viral  infections  with  similar  clinical  presentation  and 
geographical distribution were ruled out by laboratory 
tests.
The case illustrates the challenge of clinically differen-
tiating MAYV disease from classical dengue fever and 
other febrile exanthematous diseases that also circu-
late in South America, as well as the role of labora-
tory confirmation in establishing a correct diagnosis. 
Indeed, dengue fever was initially suspected consider-
ing its occurrence in most cities and places on tropical 
America, including the Amazon basin. The pathogen-
esis of debilitating symptoms in MAYV disease is still a 
poorly understood phenomenon [5], although persist-
ent infection of synovial macrophages has been docu-
mented for other closely related and also arthritogenic 
alphaviruses [6]. The results of serological studies of 
the  two  consecutive  convalescent-phase  serum  sam-
ples showed that the patient did not seroconvert with 
a switch from IgM to IgG. In most acute arboviral infec-
tions,  IgM  class-specific  antibodies  are  generally  no 
longer detectable after a period of 6-12 months post 
infection [7,8]. Considering the period for seroconver-
sion in MAYV infection, we can therefore assume that 
the time between disease onset and the last late-phase 
blood sampling in this patient was not long enough for 
to allow Ig class switching. 
Interestingly,  this  report  highlights  the  need  for 
increased  awareness  MAYV  disease  as  a  differen-
tial diagnosis in travellers or migrants returning from 
endemic areas of tropical South America with febrile 
illnesses involving peripheral rheumatism and persist-
ent arthralgia. Finally, it illustrates how travellers can 
act as signals for alert that can provide insights into 
the  risk  of  transmission  of  infections  in  certain  geo-
graphical areas.
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The  large  number  of  individuals  in  Scotland  who 
became  infected  with  the  hepatitis  C  virus  (HCV)  in 
the 1970s and 1980s leads us to expect liver-related 
morbidity  and  mortality  to  increase  in  the  coming 
years. We investigated the contribution of HCV to liver-
related  mortality  in  the  period  January  1991  to  June 
2006. The study population consisted of 26,861 indi-
viduals whose death record mentioned a liver-related 
cause (underlying or contributing). Record-linkage to 
the  national  HCV  Diagnosis  database  supplied  HCV-
diagnosed  status  for  the  study  population.  The  pro-
portion diagnosed with HCV among people dying from 
a  liver-related  cause  rose  from  2.8%  (1995-1997)  to 
4.4% (2004-June 2006); the largest increase occurred 
in those aged 35-44 years at death (7% to 17%). Among 
all deaths from a liver-related cause, an HCV-positive 
diagnosis was more likely in those who died in 2001 
or later than those who died in 1995-1997 (2001-2003: 
odds  ratio=1.4,  95%  confidence  interval:  1.1-1.7; 
2004-June 2006: 1.6, 1.3-2.0), and in those who died 
at under 55 compared with at least 55 years of age. 
HCV infection represents a significant, growing, pub-
lic health burden in Scotland in terms of early deaths 
from liver disease.
Introduction
Mortality  from  severe  liver  disease,  of  which  major 
contributing  factors  include  excessive  alcohol  con-
sumption  and  chronic  infection  with  the  hepatitis  C 
virus (HCV), is increasing in Scotland [1,2] and in other 
developed  countries,  such  as  the  United  States  of 
America [3]. About 1,500 new HCV diagnoses are made 
each year in Scotland (population 5.1 million in 2006) 
[4], and projection models of HCV-related liver disease 
forecast  significant  rises  in  morbidity  and  mortality 
over the coming decades, placing a growing clinical and 
economic  burden  on  the  Scottish  healthcare  system 
[5]. Given the large number of individuals chronically 
infected  with  HCV,  and  the  fact  that  cirrhosis  devel-
ops in 5%-15% of these individuals within 20 years of 
infection [6] and in about 20% within 30 years [7], it is 
important to ascertain the contribution of chronic HCV 
infection to liver-related mortality.
The existence of high-quality national HCV diagnosis 
and mortality databases provided the opportunity to 
use record-linkage methods to investigate the preva-
lence of diagnosed HCV infection in people who died 
from liver disease. The goals of this study were there-
fore  to  estimate  the  contribution  of  HCV  infection  to 
liver-related deaths in Scotland and to examine trends 
in this contribution over time and by age group. Up-to-
date information regarding the contribution of HCV to 
mortality from liver disease is required to inform public 
health intelligence and health service planning, and as 
a calibration check on projections.
Methods 
Study population and data sources
Death  registrations  are  held  by  the  General  Register 
Office for Scotland (GROS). The study population con-
sisted of all those who died from 1 January 1991 to 30 
June  2006,  and  whose  death  certificate  specified  a 
liver-related condition.
International  Classification  of  Diseases  (ICD)  codes 
were used to extract all records from the deaths regis-
ter in which a liver-related condition was listed as either 
the underlying cause (i.e. the disease or injury initiat-
ing the train of events leading directly to death) or a 
contributing cause of death (n=26,861). We obtained 
underlying  and  contributing  cause-of-death  codes 
from  ICD’s  ninth  revision  (ICD-9)  for  deaths  between 
1989  and  1999  and  the  tenth  revision  (ICD-10)  for 
deaths between 2000 and 2006. The relevant cause-
of-death categories were: liver cancer, alcoholic liver 
disease, nonalcoholic liver disease, viral hepatitis, and 
sequelae of viral hepatitis (Table 1). Specific mention of 
viral hepatitis C (ICD-10 B17.1, B18.2), unspecified viral 
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hepatitis  (ICD-9  070.4-6,  070.9)  as  a  cause  of  death 
was  also  noted,  to  assess  the  frequency  with  which 
HCV is mentioned on the death certificate. Liver-related 
deaths among those diagnosed HCV antibody-positive 
(with or without mention of HCV on the death record) 
were determined through record-linkage between the 
GROS deaths registry and the HCV Diagnosis database 
(details below).
Carstairs social deprivation scores (coded as quintiles) 
were available for each death record; deprivation score 
is determined from postcode sector of residence and is 
based on 2001 census variables [8]. The highest quin-
tile corresponds to the 20% most deprived localities.
The  HCV  Diagnosis  database,  maintained  by  Health 
Protection  Scotland  (HPS),  is  a  database  of  all 
individuals  who  have  been  diagnosed  HCV  positive 
in  Scotland  since  testing  began  in  1991  [9];  labora-
tory  detection  of  hepatitis  C  antibody  positivity  is  a 
requirement for inclusion. This database contains the 
following  non-named  information:  surname  Soundex 
(a  consonant-only  phonetic  encoding),  forename  ini-
tial, date of birth, sex, and postcode district of resi-
dence, as well as data concerning risk activities and 
the date of the earliest positive specimen. The data-
base contained records for 20,969 persons diagnosed 
HCV positive between 1 January 1991 and 30 June 2006 
[4].  As  no  probabilistic  linkages  between  the  GROS 
deaths register and the HCV diagnosis database were 
achieved if the HCV diagnosis record was lacking date 
of birth and two or more other identifiers, records for 
1,295 out of 20,969 HCV-diagnosed people (6%) were 
deemed to have insufficient identifiers for linkage. Of 
Table 2
Deaths from liver-related (underlying/contributing) conditions (n=26,861), and those diagnosed HCV-positive (n=871), 
multifactorial logistic regression analysis, Scotland, 1 January 1991 to 30 June 2006 
Factor Level n HCVa (%) OR 95% CI
Sex
Femaleb
Male
10,200
16,661
223
648
(2.2)
(3.9) 1.70 1.45-1.99
Age at death
<25
25-34
35-44
45-54
55+b
135
600
2,571
5,602
17,953
8
103
274
228
258
(6)
(17)
(10.7)
(4.1)
(1.4)
5.47
13.72
7.84
2.66
2.63-11.39
10.69-17.61
6.56-9.37
2.22-3.20
Year of death
Before 1995
1995-1997b
1998-2000
2001-2003
2004-2006
4,697
4,657
5,519
6,592
5,396
51
132
196
257
235
(1.1)
(2.8)
(3.6)
(3.9)
(4.4)
0.39
1.23
1.35
1.61
0.28-0.55
0.98-1.55
1.08-1.68
1.29-2.01
Deprivation quintile
First, secondb
Third
Fourth, fifth
6,967
4,797
14,940
147
145
575
(2.1)
(3.0)
(3.8)
1.27
1.36
1.00-1.61
1.12-1.64
HCV: hepatitis C virus-positive; OR: adjusted odds ratio; 95% CI: confidence interval.
aNumber of deaths among those diagnosed HCV-positive, determined through linkage to HCV Diagnosis database.
bReference.
Table 1
 Deaths from liver-related (underlying/contributing) conditions (n=26,861), and those diagnosed hepatitis C virus-positive 
(n=871), by cause-of-death category, Scotland, 1 January 1991 to 30 June 2006
Underlying/contributing cause of death n (%) HCVa (%) HCV/n %
Alcoholic liver disease
(ICD-10 K70; ICD-9 571.0-571.3)
12,018(44.7) 279 (32) 2.3
Non-alcoholic liver disease
(ICD-10 K71-77; ICD-9 570, 
571.4-571.9, 572-573)
17,304(64.4) 500 (57) 2.9
Hepatocellular carcinoma
(ICD-10 C22.0, ICD-9 155.0)
1,797(6.7) 116 13) 6.5
Viral hepatitis
(ICD-10 B15-19; ICD-9 070)
620(2.3) 456 (52) 73.5
Sequelae of viral hepatitis
(ICD-10 B94.2, R17, R18, I85.0, 
I98.2; ICD-9 789.5, 456.0)
1,811(6.7) 85 (10) 4.7
Total 26,861(100) 871 (100) 3.2
HCV: hepatitis C virus-positive.
a Number of deaths among those diagnosed HCV-positive, determined through linkage to HCV Diagnosis database.12 www.eurosurveillance.org
the records with sufficient identifiers, 68% were male, 
and 71% (14,018/19,674) were born between 1960 and 
1979.
Linkage procedure
Linkage of records between the HCV Diagnosis data-
base  and  the  GROS  deaths  registry  was  carried  out 
by  the  Information  Services  Division  (a  division  of 
NHS  National  Services  Scotland)  using  probabilistic 
record-linkage techniques [10] to determine the HCV-
diagnosed  status  of  all  individuals  whose  cause  of 
death included a liver-related condition. These meth-
ods  allow  for  matches  using  incomplete  identifiers. 
The linked dataset was anonymised (i.e. the only iden-
tifiers retained were, date of birth, sex and postcode 
district of residence) before transfer to HPS for analy-
sis. Linkages were approved by the Privacy Advisory 
Committee,  which  oversees  confidentiality  issues 
involving data held on NHS Scotland patients.
Data analysis
Logistic regression was used to estimate the associa-
tion between four epidemiological variables and diag-
nosed HCV status (i.e. whether or not linked to the HCV 
Diagnosis  database).  These  were:  sex,  age  at  death, 
year of death (with 1995–1997 specified as the refer-
ence category, because HCV testing was more limited 
before  this  period),  and  Carstairs  social  deprivation 
quintile. We did not analyse trends in mortality rates 
because  the  HCV  Diagnosis  database  has  expanded 
since its inception and people in the later stages of HCV 
disease may have been over-represented in its earlier 
years. Statistical analyses were carried out using R ver-
sion 2.4.0 [11].
 
To  estimate  the  extent  of  underreporting  of  HCV  on 
the death certificate, we computed the proportion of 
death records that were linked to the HCV Diagnosis 
database, but failed to list an HCV code as either the 
underlying or a contributing cause of death. This analy-
sis was also conducted separately for the year range 
2000-2006, as the change in cause-of-death coding to 
the ICD-10 classification in 2000 overcomes the impre-
cision in the ICD-9 codes for HCV. The main data analy-
sis was based on the linked data only.
Results 
Overall description
Between 1 January 1991 and 30 June 2006, a total of 
26,861  people  died  in  Scotland  whose  death  record 
specified  a  liver-related  condition  as  the  underlying 
or a contributing cause of death (Table 1). The major-
ity  of  liver-related  deaths  occurred  in  males  (62%; 
16,660/26,861),  and  the  median  age  at  death  was 
Table 4
Numbers of deaths from liver-related conditions, proportions of those diagnosed hepatitis C virus-positive, by age at death 
and year of death, Scotland, 1995–1997 and January 2004–June 2006
1995-1997 1998-2000 2001-2003 2004-June 2006 Total
Age at death (%) n HCVa (%) n HCVa (%) n HCVa (%) n HCVa (%) n HCVa (%)
<25 32 4 (13) 29 2 (7) 17 0 (0) 17 0 (0) 95 6 (6)
25-34 107 20 (19) 143 27 (19) 138 25 (18) 117 20 (17) 505 92 (18)
35-44 432 30 (7) 544 66 (12) 691 86 (12) 478 80 (17) 2,145 262 (12.2)
45-54 972 23 (2.4) 1,196 46 (3.8) 1,444 76 (5.3) 1,180 75 (6.4) 4,792 220  (4.6)
55+ 3,114 55 (1.8) 3,607 55 (1.5) 4,302 70 (1.6) 3,604 60 (1.7) 14,627 240 (1.6)
All ages 4,657 132 (2.8) 5,519 196 (3.6) 6,592 257 (3.9) 5,396 235 (4.4) 22,164 820  (3.7)
HCV: hepatitis.
aNumbers of deaths diagnosed HCV-positive, determined through linkage to HCV Diagnosis database.
Table 3
Deaths from a liver-related condition by period of death, mention of hepatitis C virus (HCV) in the death record, and 
linkage to the HCV Diagnosis database, Scotland, 1 January 1991 to 30 June 2006
Linked to HCV Diagnosis database
Period Mention of HCV in death recorda Yes (%) No Total (%)
1991-1999
HCV mentioned
HCV not mentioned
Total
158 (51)
150 (49)
308
45
12,617
12,662 203 (%)
2000-2006
HCV mentioned
HCV not mentioned
Total
292 (52)
271  (48)
563
48
13,280
13,328 340 (%)
1991-2006
HCV mentioned 
HCV not mentioned
Total
450 (52)
421 (48) 
871
93
25,897
25,990 543 (%)
HCV: hepatitis.
aUnlinked per cent  gives the percentage of death records not linked to the HCV Diagnosis database.13 www.eurosurveillance.org
61  years  (interquartile  range  (IQR):  51–71)  (Table  2). 
The  overall  proportion  of  deaths  linked  to  the  HCV 
Diagnosis  database  was  3.2%  (871/26,861).  The 
median age at death for individuals identified as diag-
nosed HCV-positive was 47 years (IQR: 39–58).
We  report  on  deaths  from  underlying  or  contributing 
liver-related causes (n = 26,861), but note that distri-
butions of baseline characteristics and annual trends 
were similar if the data were restricted to deaths from 
underlying  liver-related  causes  only  (n=16,767;  data 
not shown).
Mention of HCV in death records
Viral  hepatitis  C  was  listed  as  the  underlying  or  a 
contributing  cause  of  death  in  1.6%  (543/26,861)  of 
all liver-related deaths, and in 52% (450/871) of liver-
related deaths linked to the HCV Diagnosis database. 
This  proportion  remained  the  same:  292/563  (52%) 
when liver-related deaths occurring from 2000 onwards 
only (n=13,891) were considered (Table 3). 
Alcohol (ICD-10 K70, ICD-9 571.0-3) was mentioned in 
45% (12,018/26,861) of all liver-related death records 
(Table 1), but in 51% of the group aged 25–34 years at 
death (308/600). People on the HCV Diagnosis data-
base  accounted  for  17%  of  the  liver-related  deaths 
(17%)  in  the  25–34  age  group  (Table  2)  and  69%  of 
these  deaths  mentioned  an  alcohol-related  ICD  code 
(data not shown).
Odds of being diagnosed HCV-positive
Of those whose cause of death included a liver-related 
condition (either underlying or contributing), the odds 
of  being  diagnosed  HCV-positive  were  significantly 
higher for males than for females, and for those who 
died before the age of 55 years than those who died 
aged  55  or  older.  Compared  with  deaths  occurring 
1995-1997,  the  odds  of  being  HCV-diagnosed  were 
higher for deaths occurring in 2001. People who lived 
in the more deprived regions had significantly higher 
odds of being HCV-diagnosed than people who lived 
in  the  two  least  deprived  quintiles  (Table  2).  Of  the 
HCV-diagnosed individuals, 32% (278/871) were born 
between 1960 and 1979. The median interval between 
HCV diagnosis and death was 2.1 years (range -0.4 to 
14.5 years).
Table 4 compares the number and proportion of HCV-
linked deaths by age at death and year of death cat-
egories,  between  1995-1997  and  2004-June  2006.  A 
trend test showed that HCV-linked deaths formed an 
increasing proportion of liver-related deaths over time, 
from 2.8% in 1995–1997 to 4.4% in 2004–June 2006 
(p=0.012). The largest proportional increases over this 
time-span  occurred  in  people  who  died  aged  35-44 
years (from 7% to 17%) and aged 45-54 years (from 2% 
to 6%). A significant difference in the rate of change in 
the proportion of HCV-linked deaths over time across 
age  groups  was  confirmed  by  an  interaction  test 
(p<0.0001).
Discussion
Over the past 15 years, we have observed an increas-
ing  contribution  from  HCV  infection  to  mortality  due 
to liver-related causes in Scotland. Deaths increased 
steadily with time among the 35–54 years age group, 
and the largest percentage of deaths linked to the HCV 
Diagnosis  database  (31%)  were  of  people  born  from 
1950 to 1959. This is consistent with infection of young 
people in the 1970s and 1980s – before HCV was iden-
tified – and the natural history of chronic HCV infec-
tion [12]. HCV plays a much smaller role in liver-related 
deaths in older age groups mainly because relatively 
few individuals acquired infection at a late enough age.
A relatively high percentage of the liver-related deaths 
(17%)  in  the  25–34  age  group  were  HCV-diagnosed 
individuals; the majority (69%) of these death records 
mentioned  an  alcohol-related  ICD  code.  High  liver-
related mortality in this group may reflect more rapid 
development of liver disease associated with combined 
HCV infection and excessive alcohol use [13]. 
This  study  is  the  first  to  our  knowledge  that  links 
national HCV diagnosis data to national mortality data 
to chart the contribution, over time, of HCV to all liver-
related deaths [14]. Recent modelling initiatives have 
predicted  substantial  rises  in  HCV-related  mortality 
in the next decade – for example, it is predicted that 
deaths will increase 2.8-fold between 2000 and 2020 
in  the  United  States  (US)  [15],  and  increase  1.7-fold 
between 2005 and 2020 (78 increasing to 129) in cur-
rent/former injecting drug users (IDUs) in Scotland [16]. 
In this study, we observed a 1.3-fold rise in the number 
of liver-related deaths of people diagnosed with HCV 
infection (71 to 92) from 2000 to 2005, a rate which, 
if maintained over a further 10 years, would be even 
steeper  than  the  2005–2020  projections  for  IDUs  in 
Scotland.  With  mortality  from  liver  disease  becom-
ing  increasingly  associated  with  HCV  infection,  the 
importance of offering tests to individuals (particularly 
those  under  55  years  of  age)  presenting  to  hospital 
with an unexplained liver-related condition cannot be 
overemphasised.
It is notable that 48% of the records for liver-related 
deaths that linked to the HCV Diagnosis database did 
not mention HCV as either the underlying or a contrib-
uting cause of death. This finding has strong implica-
tions for public health decision making regarding the 
HCV epidemic. Underreporting of HCV on death certifi-
cates is a problem for many countries, such as England 
[17] and the US [3,18,19], undermining studies that aim 
to determine HCV infection’s contribution to mortality 
from liver disease by using cause-of-death coding on 
death certificates.
Using record-linkage to HCV diagnosis data, we deter-
mined that 3.2% of all liver-related deaths were related 
to HCV infection. This proportion is substantially lower 
than in previous reports that have considered the role 
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– for example, 15% (of 30,933 deaths in 1998) [18] and 
16% (56/233 deaths in 2000) [19] in two studies from 
the US. This difference may be due to a higher preva-
lence of problem alcohol use in the Scottish population 
[20], particularly for death at a relatively young age: 
we note that 45% of all liver-related deaths and 69% of 
liver-related deaths in the 25-34 years age group men-
tioned one or more alcohol-related ICD codes.
Our  study  has  important  strengths  and  limitations. 
The use of a national deaths register to identify liver-
related  deaths  has  provided  considerable  statisti-
cal precision. The main limitations relate to a lack of 
information  about  chronic,  versus  resolved,  infection 
on  the  HCV  Diagnosis  database,  and  to  record-link-
age errors. We assumed that all individuals who died 
from  a  liver-related  cause  and  were  diagnosed  with 
HCV were chronically infected. Given that about 26% 
of  those  ever  diagnosed  antibody-positive  appear  to 
achieve spontaneous viral clearance [21], we may have 
overestimated  the  proportion  of  liver-related  deaths 
associated with chronic HCV infection, although this is 
likely to be offset by underestimation due to unrecov-
ered linkages – for example, if critical identifiers were 
erroneous or missing.
A  larger  problem  of  underestimation  exists  because 
60% to 70% of the chronically HCV-infected population 
in Scotland are estimated to remain undiagnosed [12]. 
Because these ‘missing’ HCV-related deaths have not 
been added to the known HCV-related deaths reported 
here, we have quantified only the lower bound of the 
true contribution of HCV infection to liver-related mor-
tality. It is likely, however, that more than 60%-70% of 
people  with  HCV  infection  presenting  with  fatal  liver 
disease will be tested and diagnosed. Related to this 
issue,  we  note  that  if,  say,  postmortem  HCV  testing 
increased  over  the  study  period  this  would  account 
for  part  of  the  increasing  trend  in  the  proportion  of 
HCV-diagnosed  liver-related  deaths.  Similarly,  if  the 
majority of the 6% of HCV Diagnosis records that were 
excluded from analysis (because of insufficient identi-
fiers) were from the early part of the database period, 
then the increasing trend observed in the proportion 
of deaths that were HCV-diagnosed might be overesti-
mated. No indication of such a distribution was found, 
however.
Because injecting drugs is the commonest risk factor 
for acquiring HCV infection in Scotland, the adjusted 
odds ratios reported here for sex and social depriva-
tion are partly capturing differences in IDU prevalence: 
a  higher  proportion  of  males  than  females  are  IDUs, 
and IDU prevalence is greatest for people who live in 
the most deprived areas [22].
As  we  lacked  data  regarding  problem  alcohol  use, 
we  have  not  been  able  to  estimate  the  relative  con-
tributions  of  HCV  infection  and  alcohol  consumption 
to  liver-related  mortality  in  people  diagnosed  with 
HCV  infection;  this  is  of  particular  interest  for  cases 
in whom alcoholic liver disease was specified as the 
underlying cause of death. High levels of alcohol con-
sumption  have  been  implicated  as  contributing  to 
premature death in people with chronic HCV infection 
[23],  consistent  with  a  synergistic  effect  of  alcohol 
and chronic HCV infection on the development of liver 
disease [13]. IDUs – who comprise the majority of the 
chronically-infected HCV population in Scotland – have 
been  reported  to  have  a  relatively  high  prevalence 
(37%–53%) of heavy alcohol consumption (defined as 
a score of eight or more on the Alcohol Use Disorders 
Identification  Test  [AUDIT]  scale  [24,25],  or  as  two 
positive  responses  in  the  CAGE  questionnaire  [26]). 
Consequently,  the  increase  over  time  in  the  propor-
tion of liver-related deaths linked to the HCV Diagnosis 
database that we observed may be partly attributed to 
a rise in problem alcohol use, if alcohol consumption 
has  increased  in  the  HCV-diagnosed  population  over 
the study period.
In conclusion, HCV infection constitutes a significant, 
growing, public health burden in Scotland in terms of 
mortality from liver disease. Mortality from HCV-related 
liver disease is anticipated to increase as the popula-
tion infected in the 1970s and 80s ages, those infected 
in the 1990s enter their second or third decade after 
HCV infection, and the size of the chronically-infected 
population grows. A better understanding of the risk 
factors  associated  with  developing  HCV-related  liver 
disease will improve treatment and survival.
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Hand  hygiene  is  the  most  effective  way  to  stop  the 
spread  of  microorganisms  and  to  prevent  health-
care-associated  infections  (HAI).  The  World  Health 
Organization launched the First Global Patient Safety 
Challenge - Clean Care is Safer Care - in 2005 with the 
goal to prevent HAI globally. This year, on 5 May, the 
WHO’s initiative SAVE LIVES: Clean Your Hands, which 
focuses  on  increasing  awareness  of  and  improving 
compliance  with  hand  hygiene  practices,  celebrated 
its  second  global  day.  In  this  article,  four  Member 
States  of  the  European  Union  describe  strategies 
that were implemented as part of their national hand 
hygiene  campaigns  and  were  found  to  be  notewor-
thy.  The  strategies  were:  governmental  support,  the 
use  of  indicators  for  hand  hygiene  benchmarking, 
developing national surveillance systems for auditing 
alcohol-based hand rub consumption, ensuring seam-
less coordination of processes between health regions 
in  countries  with  regionalised  healthcare  systems, 
implementing the WHO’s My Five Moments for Hand 
Hygiene, and auditing of hand hygiene compliance.
Introduction
Ignaz  Semmelweis  first  demonstrated  in  1847  that 
good hand disinfection was able to prevent puerperal 
fever [1-2] and evidence continues to show that hand 
hygiene is the simplest, most effective way to prevent 
cross-transmission of microorganisms and healthcare-
associated infections (HAI) [3-5]. Despite all the data 
that are available supporting the benefits of performing 
hand hygiene, strict compliance of healthcare workers 
(HCW)  with  recommended  hand  hygiene  practices  is 
very difficult to achieve and even when it is achieved, 
it is very difficult to sustain. Factors found to be associ-
ated with poor hand hygiene practices include, among 
others: being an assistant physician or assistant nurse 
rather than a physician or a nurse, working on a week-
day, having many hand hygiene opportunities per hour 
of  patient  care,  performing  activities  with  high  risk 
of  cross-transmission  of  microorganisms,  working  in 
high-risk areas and wearing gloves and gowns [4,6,7]. 
No  single  intervention  is  adequate  enough  to  bring 
about  change  in  behaviour,  and  in  fact,  for  hand 
hygiene practices to be changed and results to be sus-
tainable,  multimodal  approaches  and  complex  inter-
ventions have been shown to be necessary [7-9]. 
In 2005, the World Health Organization’s (WHO) World 
Alliance  for  Patient  Safety,  launched  the  First  Global 
Patient  Safety  Challenge,  Clean  Care  is  Safer  Care 
(http://www.who.int/gpsc/background/en/index.
html)  [10],  which  targeted  the  prevention  of  HAI. 
Subsequently,  in  2009,  it  launched  the  SAVE  LIVES: 
Clean Your Hands (http://www.who.int/gpsc/5may/en)
initiative, highlighting the importance of hand hygiene 
and  providing  guidelines  and  toolkits  for  the  best 
implementation of hand hygiene [9,11,12] 
The purpose of this article is to highlight one important 
aspect of the national hand hygiene campaigns from 
four  Member  States  of  the  European  Union  (EU)  that 
we  felt  to  be  noteworthy  and  successful  in  changing 
HCW’s hand hygiene practices.
Belgium: governmental support 
as a key factor for success
In  Belgium  three  multimodal,  country-wide  hand 
hygiene campaigns were organised from 2005 to 2009 
[13]. The purpose of these campaigns was to raise the 
awareness of HCW in all hospitals and, in doing so, to 
increase their adherence to good hand hygiene prac-
tices. The main foci of the campaigns were to improve 
the use of alcohol-based hand rubs (ABHR) by HCW and 
to measure their compliance with hand hygiene before 
and after each patient intervention. In order to increase 
adherence,  performance  feedback,  education,  work-
place reminders and patient empowerment were used. 17 www.eurosurveillance.org
Government support, one of the WHO’s key recommen-
dations for planning national hand hygiene campaigns, 
was one of the most important reasons for success of 
the Belgian national campaigns [9]. The Federal Public 
Service (FPS) for Public Health, Food Chain Safety and 
Environment gave a strong political commitment dur-
ing all three campaigns. The Belgian Antibiotic Policy 
Coordination  Committee  (BAPCOC),  together  with  the 
FPS, were the core groups supporting the campaigns. 
The FPS had a dual role: it funded the campaigns and 
was part of the national task force that was respon-
sible for their organisation. In addition, the FPS sup-
ported the campaigns by sending a written invitation 
to all Belgian hospitals, requesting voluntary partici-
pation in Belgium’s national hand hygiene campaigns. 
In order to solidify the engagement of hospitals at an 
institutional level, positive replies indicating the inten-
tion to participate in the national hand hygiene cam-
paigns, had to be returned to the FPS with signatures 
from the hospital directors and infection control teams. 
Other  governmental  activities  included  press  confer-
ences  at  the  launch  of  each  hand  hygiene  campaign 
by the Belgian Minister of Social Security and Public 
Health  and  campaign  materials  in  French  and  Dutch, 
made  available  on  the  Federal  platform  for  hospital 
hygiene website (www.hicplatform.be).
Each  of  the  three  national  hand  hygiene  campaigns 
resulted in a significant increase in hand hygiene com-
pliance in HCW and also a higher consumption of ABHR 
[14-16].  Compliance  with  hand  hygiene,  measured  by 
direct observation, increased significantly from 49% to 
69% during the first campaign, from 53% to 69% dur-
ing the second campaign and from 58% to 69% during 
the  third  campaign.  Hospital  participation  and  com-
mitment, which was voluntary, was 95% for acute care 
hospitals, 65% for long-term care hospitals and 60% 
for psychiatric hospitals, for all campaigns.
High hospital participation rate and the improvement 
of  hand  hygiene  compliance  in  all  types  of  HCW  are 
indications that behaviour is changing. In view of these 
positive outcomes, hand hygiene campaigns have now 
become a priority for the Belgian government, and a 
separate budget for a new campaign will be allocated 
every  two  years.  The  next  campaign  will  be  held  in 
November, 2010. 
France: indicators and governmental 
involvement as key elements for the 
successful implementation of hand hygiene
Infection control in France began when infection con-
trol  committees  were  created  in  public  and  private 
hospitals in 1988 and 1999, respectively, following a 
ministerial decree from the Ministry of Health in 1988 
[17,18]. 
The first phase of the French national programme for 
infection  control,  was  created  in  1993  and  has  been 
responsible  for  strengthening  infection  control  prac-
tices  locally  and  nationally,  for  the  creation  of  sur-
veillance  networks  to  monitor  and  prevent  HAI,  and 
preventing  the  emergence  and  spread  of  antimicro-
bial resistance in micro-organisms [19,20]. The French 
Institute  for  Public  Health  Surveillance  (Institut  de 
Veille  Sanitaire  (InVS))  has  developed  the  Réseau 
d’alerte,  d’investigation  et  de  surveillance  des  infec-
tions  nosocomiales  (RAISIN)  (http://www.invs.sante.
fr/surveillance/raisin/), which is an early warning sur-
veillance system [19,21]. 
The  second  phase  of  the  French  national  infection 
control  programme,  from  2005  to  2008,  promoted 
the implementation of five national quality indicators 
which are used to benchmark hospital performance in 
infection control. These indicators were a breakthrough 
in the field of infection control practices, and through 
benchmarking and public reporting, 89% of healthcare 
facilities  in  France  attained  the  highest  rates  of  per-
formance. The indicators can be found on the website 
of the Ministry of Health [20] and are listed below:
•	   Global  indicator  of  infection  control  (ICALIN) 
(http://www.icalin.sante.gouv.fr/);
•	   Surgical  site  infection  surveillance  indicator 
(SURVISO)  (http://www.sante-sports.gouv.fr/sur-
viso-indicateur-de-realisation-d-une-surveillance-
des-infections-du-site-operatoire-iso.html); 
•	   Alcohol-based  hand  rub  consumption  indicator 
(ICSHA) (http://www.sante-sports.gouv.fr/l-indica-
teur-icsha.html);
Table
Use of alcohol-based hand rubs from 4,076 hospital units in 2008 in Germany
Type of unit Number of hospitals Number of units Patient days L/year
mL/PD
P10a P25b Median P75c P90d
ICU 303 556 1,223,229 94,744 33 53 73 95 126
Non-ICU 343 3,520 28,065,590 496,824 8 13 14 23 33
ICU: intensive care unit; PD: patient days.
a10% Percentile. 
b25% Percentile. 
c75% Percentile. 
d90% Percentile.18 www.eurosurveillance.org
•	 Incidence  of  meticillin-resistant  Staphylococcus 
aureus  (MRSA)  indicator  (SARM)  (http://www.
sante-sports.gouv.fr/sarm-staphylococcus-
aureus-resistant-a-la-meticilline-dans-les-prelev-
ements-a-visee-diagnostique-en-2005-et-2006-
pour-1000-journees-d-hospitalisation.html), 
measuring incidence of MRSA infections per 1,000 
patient-days;
•	   Antibiotic  stewardship  and  consumption  indica-
tor  (ICATB)  (http://www.sante-sports.gouv.fr/
icatb-indice-composite-de-bon-usage-des-antibi-
otiques.html). 
In  2008,  France  organised  a  national  hand  hygiene 
campaign,  available  on  a  dedicated  space  on  the 
Ministry  of  Health’s  website  Mission  mains  propres 
(http://www.sante-sports.gouv.fr/mission-mains-pro-
pres.html) (Mission clean hands) [13], for which there 
was strong governmental support, mostly by providing 
finances for auditing of hand hygiene compliance.
Germany: the key to success: standardising 
the audit of ABHR as part of the 
national surveillance system
The German national hand hygiene campaign AKTION 
Saubere  Hände  (http://www.praxis-page.de/ash/
index2.htm) was launched in January 2008 and is sup-
ported  by  the  German  Ministry  of  Health.  The  basic 
premise  of  this  campaign  is  the  implementation  of 
multimodal  interventions  to  improve  hand  hygiene 
compliance. The five key intervention tools it uses are: 
mandatory  educational  lectures  for  HCW,  increased 
availability of ABHR in hospitals, administrative sup-
port  of  the  hand  hygiene  campaign,  implementation 
of the WHO’s My Five Moments of Hand Hygiene and 
the  evaluation  of  compliance  by  measuring  ABHR 
consumption. 
The  German  Krankenhaus-Infektions-Surveillance-
System  (KISS)  (http://www.nrz-hygiene.de/)  is  a 
surveillance  system  of  HAI.  Within  this  surveillance 
system, KISS established a new module named HAND-
KISS  (http://www.nrz-hygiene.de/surveillance/hand.
htm),  a  surveillance  system  that  measures  the  ABHR 
usage as a surrogate measure of compliance with hand 
hygiene.
To  date,  660  healthcare  institutions,  such  as  hospi-
tals, senior care centres, rehabilitation centres, ambu-
latory  dialysis  centres  and  emergency  services,  feed 
their  ABHR  consumption  data  on  a  mandatory  basis 
into HAND-KISS. These data are reported annually in 
millilitre (mL), by number of annual patient days (PD) 
per hospital unit type (intensive care unit or not), and 
by hospital. HAND-KISS calculates the ABHR in mL per 
PD for each unit and provides reference data, stratified 
according to each unit’s specialty. 
The HAND-KISS consecutive data from 2007 and 2008 
and  AHBR  consumption  data  from  hospitals  partici-
pating in the AKTION Saubere Hände are presented in 
the Table. From 2007 to 2008, there was a statistically 
significant increase of 13% in ABHR consumption in all 
hospital units participating in HAND-KISS and AKTION 
Saubere Hände.
Measuring  consumption  of  ABHR  is  a  good  way  to 
assess compliance with hand hygiene, as it is difficult 
to obtain precise data on compliance by auditing the 
number  of  hand  hygiene  observations.  Satisfactory 
inter-rater reliability is hard to achieve when measur-
ing hand hygiene observations and in fact, inter-rater 
reliability ranged between 30% and 60% when it was 
assessed  during  the  German  national  hand  hygiene 
campaign  (Reichardt,  unpublished  data).  Due  to  this 
variability,  hand  hygiene  compliance  rates  cannot 
be  used  to  accurately  allow  a  comparison  of  rates 
between hospitals, and quantitative interpretation of 
data  should  be  done  with  caution.  Measurement  of 
ABHR consumption provides a practical and potentially 
more  reliable  system  to  assess  quantitative  changes 
in hand hygiene behaviour and provides a benchmark-
ing system to compare between hospitals. HAND-KISS 
is the first surveillance system to provide crude data 
of the distribution of ABHR for benchmarking between 
hospitals.
United Kingdom - England: My Five 
Moments for Hand Hygiene and beyond
From 2009 to 2010, the cleanyourhands (http://www.
npsa.nhs.uk/cleanyourhands)  campaign  in  England 
and Wales embraced the WHO’s My Five Moments for 
Hand  Hygiene  aiming  to  integrate  hand  hygiene  into 
every aspect of patient care and to emphasise to HCW 
that the point of patient care is the critical moment to 
stop cross-transmission of micro-organisms and thus 
preventing HAI.
Although My Five Moments for Hand Hygiene was ini-
tially developed for the inpatient hospital setting by the 
University  of  Geneva  Hospitals  [12],  cleanyourhands 
has attempted to expand this approach in England and 
Wales across all types of National Health System (NHS) 
trust, from the acute inpatient setting to ambulances 
and mental health institutions.
In order to implement the elements of My Five Moments 
for Hand Hygiene, educational material and practical 
tools for training were developed for infection control 
practitioners to use, but also to train and educate other 
staff.  A  key  resource  that  was  developed  was  a  film 
based on one patient’s journey through the NHS, from 
ambulance to hospital and back home, illustrating the 
multitude of opportunities that were available for hand 
hygiene and how the Five Moments for Hand Hygiene 
can be applied in different care settings.
Other  activities  included  a  series  of  regional  one-
day  workshops  introducing  My  Five  Moments  for 
Hand  Hygiene  for  infection  control  staff  and  those 
responsible  for  infection  control  training  in  England 
and  Wales.  Feedback  from  the  workshops  has  been 19 www.eurosurveillance.org
overwhelmingly positive with 95% of respondents con-
sidering  them  good  or  excellent.  Subsequently,  the 
cleanyourhands campaign also facilitated a dedicated 
workshop for infection control and training representa-
tives from the ambulance service. 
To  further  highlight  the  Five  Moments  for  Hand 
Hygiene, an online game called Wi Five? (http://www.
npsa.nhs.uk/cleanyourhands/resource-area/wi-five-
game) was created and launched for the WHO’s Save 
Lives: Clean Your Hands initiative on 5 May 2009, as a 
tool for infection control teams to educate and engage 
staff in this WHO initiative. In the approximately four 
months  following  its  launch,  the  Wi  Five?  game  was 
played 37,362 times. Work is now underway to develop 
the game further, adding other scenarios to represent 
more care settings. 
United Kingdom – Scotland: auditing as a 
key factor for successful implementation 
of hand hygiene campaigns
In  2005,  the  Scottish  Minister  for  Health  and 
Community Care participated in the First Global Patient 
Safety Challenge, Clean Care is Safer Care [22,23] and 
pledged to develop and fund a national hand hygiene 
campaign in Scotland. Consequently, in January 2007, 
Scotland’s  campaign  Germs.  Wash  your  hands  of 
them  (http://www.washyourhandsofthem.com/)  was 
launched  by  Health  Protection  Scotland  (HPS).  The 
campaign is funded until March 2011 and includes both 
professional  and  public  elements.  Campaign  activi-
ties include educational posters for staff and visitors 
in  acute  and  community  healthcare  settings,  public 
media campaigns, information for children, leaflets for 
the  public  and  for  healthcare  staff,  credit  card-sized 
fliers  depicting  My  Five  Moments  for  Hand  Hygiene 
[12], research activities, presentation of national hand 
hygiene compliance data, a dedicated enquiry service 
(including telephone and email inbox enquiry service) 
and a campaign website.
Auditing hand hygiene compliance is a key method to 
monitor hand hygiene compliance in the Scottish hand 
hygiene campaign and is in accordance with the recom-
mendations in the WHO’s My Five Moments for Hand 
Hygiene. An audit tool and a supporting protocol were 
developed by HPS to ensure a standard methodology 
for data collection [24] and were adopted in Scotland 
for use in acute healthcare settings. The Scottish hand 
hygiene  compliance  data  that  are  collected  are  pub-
lished by HPS [25]. 
Local  campaign  activities  at  each  National  Health 
Service (NHS) board in Scotland are implented by the 
Local  Health  Board  Coordinators  for  hand  hygiene 
(LHBCs).  The  LHBCs  are  employed  to  perform  audits 
of hand hygiene compliance, to promote hand hygiene 
practice among HCW and to raise awareness of cam-
paign  materials.  Initial  training  for  the  LHBCs  in  the 
use of the audit protocol is provided by HPS and train-
ing updates are offered regularly. These are necessary 
because  auditors  can  report  different  hand  hygiene 
rates depending on their training [26] and any observa-
tion method will be susceptible to an inherent observer 
bias  [27].  For  this  reason,  a  quality  assurance  exer-
cise for LHBCs was undertaken and results indicated 
good inter-rater reliability for observed hand hygiene 
behaviour.
Local Health Board Coordinators for hand hygiene per-
form audits in acute healthcare settings during manda-
tory national audit periods. They measure compliance 
of  HCWs  by  observing  20  opportunities  for  hand 
hygiene during the course of one working day. Fifteen 
one-day audits are conducted during each mandatory 
audit period, which equates to 300 opportunities per 
NHS board. After every audit period, the data are sub-
mitted to HPS for quality assurance and analysis. 
The  campaign  has  helped  the  NHS  boards  to  meet, 
and even exceed, the hand hygiene compliance target 
of 90% set by the Scottish Government for November 
2008.  In  February  2007,  the  first  audit  period,  hand 
hygiene  compliance  across  NHS  Scotland  for  acute 
healthcare settings was 68%, and in the latest report 
published in January 2010, national hand hygiene com-
pliance was 94% [25]. In fact, national hand hygiene 
compliance  has  remained  above  90%  since  August 
2008. The next phase of the campaign will focus on 
sustainability of hand hygiene improvements as well 
as extension into the non-NHS healthcare sector. 
Conclusions and perspectives
Adherence of HCW to good hand hygiene practices is 
necessary during all aspects of patient care. Despite all 
the evidence supporting the benefits of hand hygiene, 
compliance with hand hygiene among HCW is low, and 
there is still much room for improvement to ensure that 
patients  remain  free  from  HAI.  Only  complex,  multi-
modal interventions have been shown to change HCW 
behaviour and to achieve high rates of compliance and 
sustainability.
Although  compliance  with  good  hand  hygiene  prac-
tices  represents  an  important  part  of  infection  con-
trol and prevention of HAI, other important practices, 
for  instance  the  prudent  use  of  antibiotics,  must  be 
strongly  reinforced  and  used  in  parallel  with  hand 
hygiene. Preventing healthcare-associated infections, 
such  as  catheter-associated  blood-stream  infections 
and Clostridium difficile colitis, also require multimo-
dal strategies, examples of which are education, feed-
back and guidance for HCW.
Hand hygiene campaigns in the EU Member States can 
range from local hospital-based hand hygiene activi-
ties  to  national  campaigns  [13].  Important  factors  in 
the support and success of national campaigns include 
governmental  support,  use  of  indicators  for  bench-
marking,  national  surveillance  systems  for  auditing 
AHBR consumption, coordination of processes between 
health  regions,  implementation  of  hand  hygiene 20 www.eurosurveillance.org
toolkits and guidelines, and auditing and feedback of 
hand hygiene compliance.
In accordance with the Council Recommendation of the 
European Commission of 9 June 2009 on patient safety 
[28], which includes the prevention and control of HAI, 
the implementation of best practices and infection pre-
vention and control programmes are important issues 
for the EU Member States . The benefits of complying 
with good practices of hand hygiene in the EU are now 
being recognised and many Member States are making 
hand hygiene a priority, frequently within the frame-
work of patient safety, and are developing strategies 
or adapting or adopting those already used by others. 
In  order  to  further  highlight  the  importance  of  hand 
hygiene and to increase the awareness and communi-
cation between the EU Member States, Belgium, as part 
of the Belgian EU Presidency celebration, will organise 
a conference in November 2010, during which a hand 
hygiene workshop will be held. This will be arranged 
in collaboration with the WHO and the European Centre 
for Disease Prevention and Control (ECDC), to provide 
a further platform and tools for raising awareness and 
implementing best hand hygiene practice in Europe.
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